How is brivaracetam different from levetiracetam?

It is the 4-propyl analog of levetiracetam and binds the same SV2A target, but with roughly 15-30 times higher affinity and greater selectivity, plus faster brain entry. In practice this can mean efficacy at lower doses and, for some patients, fewer behavioral side effects, though it shares the same class warnings.

Is brivaracetam a nootropic?

Chemically it belongs to the racetam family, but it is a serious FDA/EMA-approved antiepileptic and a US Schedule V controlled substance, not a lifestyle cognitive enhancer. Any use for cognition would be off-label and requires medical supervision.

Does it need a choline source like other racetams?

No. Its mechanism is SV2A modulation, not the cholinergic action associated with piracetam-type racetams, so the usual choline-pairing advice does not apply. It is a prescription drug managed by a physician.

ApprovedFDA approvedStrong evidence

Brivaracetam

Name: Brivaracetam
Creator: MolekulaX

SV2A-selective antiepileptic, the 4-propyl analog of levetiracetam; an FDA/EMA-approved prescription drug within the racetam chemical family.

NootropicRacetamAntiseizure medicationRacetamNeuroprotectionGlutamateGABA

Pharmacology

ClassRacetam · Neuroprotection

Primary targetHigh-affinity ligand of synaptic vesicle protein SV2A

Targets3 receptor targets

Half-life~9 h

Onset~1 h

EvidenceStrong evidence

Affected systemsGlutamateGABA

Contents

WHAT IS BRIVARACETAM?

Detailed overview

Brivaracetam (Briviact, UCB-34714) is a prescription antiepileptic and the 4-propyl analog of levetiracetam, binding synaptic vesicle glycoprotein 2A (SV2A) with roughly 15-30 times higher affinity and greater selectivity. It reduces the abnormal presynaptic neurotransmitter release that drives seizures, penetrates the brain rapidly, and can be started at an effective dose without titration. It is FDA- and EMA-approved (2016) as adjunctive and monotherapy for focal (partial-onset) seizures and is a US Schedule V controlled substance. It sits in the racetam chemical family but is a serious Rx drug, not a lifestyle nootropic; human evidence rests on multiple phase III randomized controlled trials and a Cochrane review (PMID 24256083, 24116853, 35285519).

Mechanism

Selective high-affinity SV2A ligand

Half-life

~9 h

Onset

~1 h (fast CNS entry)

Legal status

Rx (FDA/EMA); US Schedule V

Receptor profile

SV2A synaptic vesicle proteinStrong
Presynaptic neurotransmitter releaseModerate
Neuronal voltage-gated sodium channelsWeak

Safety

Side effects, stop signs, contraindications

Side effects · 6

Somnolence and sedation, the most common adverse effect, especially early in treatment
Dizziness and balance disturbance, dose-dependent
Fatigue and lethargy
Nausea and vomiting, mild gastrointestinal discomfort
Psychiatric and behavioral reactions: irritability, anxiety, depression, aggression
Coordination difficulties and unsteady gait, at higher doses

Contraindications · 6

Hypersensitivity to brivaracetam or levetiracetam
Pregnancy and breastfeeding: limited data, only under specialist supervision
Suicidal ideation or psychiatric history: antiepileptic class warning, close monitoring
Hepatic impairment: dose reduction required (hepatic metabolism)
Do not stop abruptly: withdrawal seizure risk, gradual tapering is required
Alcohol and CNS depressants: additive sedation and psychomotor impairment

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

J Med Chem. 2004;47(3):530-49.

Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity.

Kenda BM, Matagne AC, Talaga PE, et al.

PMID: 14736235Open

Epilepsia. 2016;57(2):201-9.

Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.

Nicolas JM, Hannestad J, Holden D, et al.

PMID: 26663401Open

Epilepsia. 2014;55(1):47-56.

Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial.

Ryvlin P, Werhahn KJ, Blaszczyk B, et al.

PMID: 24256083Open

Epilepsia. 2014;55(1):38-46.

Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial.

Kwan P, Trinka E, Van Paesschen W, et al.

PMID: 24116853Open

Cochrane Database Syst Rev. 2022;3(3):CD011501.

Brivaracetam add-on therapy for drug-resistant epilepsy.

Bresnahan R, Panebianco M, Marson AG.

PMID: 35285519Open

Neurology. 2007;69(10):1027-34.

Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model.

Kasteleijn-Nolst Trenite DG, Genton P, Parain D, et al.

PMID: 17785672Open

FAQ

SV2A-selective antiepileptic, the 4-propyl analog of levetiracetam; an FDA/EMA-approved prescription drug within the racetam chemical family.

Have a question about Brivaracetam?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic

FormulaC11H20N2O2

UpdatedJuly 9, 2026

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA

Updated: July 9, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.